
    
      In this phase 2 study, the target population is patients with recurrent or persistent
      metastatic endometrial cancer. The mutation status of c-MET gene will be tested and only
      patients with c-MET mutation will be enrolled. After enrollment, Crizotinib 250 mg bid will
      be used orally. CT scan or MRI will be used to determine the response. Crizotinib will be
      continued till disease progression. Primary end is objective response rate. The secondary
      endpoints include progression-free survival, overall survival and safety profiles.
    
  